Magnetic, biocompatible FeCO3 nanoparticles for T2-weighted magnetic resonance imaging of in vivo lung tumors

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2006)Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis Ann Thorac Surg 82 408-415

[3] Soerjomataram I(2017)Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline Pract Radiat Oncol 7 295-301

[4] Siegel RL(2008)New technologies for human cancer imaging J Clin Oncol 26 4012-4021

[5] Torre LA(2015)Molecular magnetic resonance imaging in cancer J Transl Med 13 313-903

[6] Jemal A(1909)Application of multiparametric MR imaging to predict the diversification of renal function in miR29a-mediated diabetic nephropathy Sci Rep 2021 11-1326

[7] El-Sherif A(2009)Bioresponsive, cell-penetrating, and multimeric MR contrast agents Acc Chem Res 42 893-565

[8] Gooding WE(2016)MRI contrast agents: classification and application (review) Int J Mol Med 38 1319-1350

[9] Santos R(2012)Gd(iii) chelates for MRI contrast agents: from high relaxivity to “smart”, from blood pool to blood–brain barrier permeable MedChemComm 3 552-1198

[10] Pettiford B(2016)Gadolinium deposition in the brain Magn Reson Imaging 34 1346-1364

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2006)Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis Ann Thorac Surg 82 408-415

[3] Soerjomataram I(2017)Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline Pract Radiat Oncol 7 295-301

[4] Siegel RL(2008)New technologies for human cancer imaging J Clin Oncol 26 4012-4021

[5] Torre LA(2015)Molecular magnetic resonance imaging in cancer J Transl Med 13 313-903

[6] Jemal A(1909)Application of multiparametric MR imaging to predict the diversification of renal function in miR29a-mediated diabetic nephropathy Sci Rep 2021 11-1326

[7] El-Sherif A(2009)Bioresponsive, cell-penetrating, and multimeric MR contrast agents Acc Chem Res 42 893-565

[8] Gooding WE(2016)MRI contrast agents: classification and application (review) Int J Mol Med 38 1319-1350

[9] Santos R(2012)Gd(iii) chelates for MRI contrast agents: from high relaxivity to “smart”, from blood pool to blood–brain barrier permeable MedChemComm 3 552-1198

[10] Pettiford B(2016)Gadolinium deposition in the brain Magn Reson Imaging 34 1346-1364